Clinical Trial Details
— Status: Terminated
Administrative data
| NCT number |
NCT04870827 |
| Other study ID # |
10000136 |
| Secondary ID |
000136-H |
| Status |
Terminated |
| Phase |
|
| First received |
|
| Last updated |
|
| Start date |
June 7, 2021 |
| Est. completion date |
May 18, 2022 |
Study information
| Verified date |
March 2023 |
| Source |
National Institutes of Health Clinical Center (CC) |
| Contact |
n/a |
| Is FDA regulated |
No |
| Health authority |
|
| Study type |
Observational
|
Clinical Trial Summary
Background:
Heart failure (HF) is a public health burden. Studies have shown a link between inflammation,
myocardial dysfunction, and HF. Researchers want to use psoriasis as a disease model of
chronic inflammation to further study the link between inflammation and myocardial
dysfunction.
Objective:
To learn if chronic inflammation affects the heart and if taking a biological medicine for
chronic inflammation helps improve how the heart works.
Eligibility:
Adults ages 18 and older who have moderate to severe psoriasis, and healthy adult volunteers.
Design:
Participants will be screened with a medical history. They may take a pregnancy test.
Healthy volunteers will have 1 visit. Those with psoriasis will have a second visit 1 year
later.
Participants may give blood samples. They may have a heart function test. They may have a
heart imaging test, and may get a contrast agent. If so, it will be injected into a vein.
Participants may have positron emission tomography/computed tomography tests. They will lie
on their back on a padded table with their arms straight overhead. They may get radioactive
drugs through an intravenous (IV) catheter. They will get stress medicines through the IV.
These drugs mimic exercise and increase blood flow through the heart.
Participants may have cardiac magnetic resonance imaging. The scanner is a large tube.
Participants will lie on a table that slides in and out of the tube. They will get gadolinium
contrast in a vein to improve the pictures. They may get stress medicines. Coils will be used
to help make the pictures.
Participation for healthy volunteers will last 1-2 days. Participation for those with
psoriasis will last 14 months.
...
Description:
Study Description:
Heart failure (HF) remains a significant public health burden despite expanding and improving
treatment options. Clinical and pre-clinical studies have demonstrated compelling
relationships between inflammation, myocardial dysfunction, HF and adverse clinical outcomes.
In this study to be conducted at the NIH Clinical Center, we propose to utilize psoriasis as
a disease model to study how chronic inflammation effects myocardial perfusion, measured by
myocardial flow reserve (MFR) on positron emission tomography (PET) and cardiac MRI (CMR),
and myocardial function and tissue composition measured by multi-modality cardiovascular
imaging.
Objectives:
1. To test the hypothesis that chronic inflammation is a driver of perturbances in
myocardial perfusion, function, and tissue composition
2. To test the hypothesis that biologic treatment for psoriasis will be associated with
longitudinal improvement in myocardial perfusion, function, and tissue composition
3. To characterize immune cell subsets and their association with myocardial perfusion,
function, and tissue composition in chronic inflammation
4. To explore how chronic inflammation may alter myocardial energetics and metabolism
Endpoints:
Primary outcomes will be:
Myocardial perfusion, as assessed by myocardial flow reserve (MFR), in subjects with moderate
to severe psoriasis compared to matched healthy controls.
Secondary outcomes will be:
Change in MFR in subjects with psoriasis on biologic therapy at 1 year follow-up compared to
baseline.
Diastolic function (on echocardiogram), myocardial mechanics (on echocardiogram and CMR),
myocardial edema and inflammation, and interstitial fibrosis (on CMR) in subjects with
moderate to severe psoriasis compared to matched healthy controls.
Change in diastolic function, myocardial mechanics, myocardial edema and inflammation, and
interstitial fibrosis in subjects with psoriasis on biologic therapy at 1 year follow- up
Exploratory outcomes will be:
Immune cell subsets by flow cytometry in subjects with 7 moderate to severe psoriasis
compared to matched healthy controls
Rest and stress left ventricular oxygen consumption (MVO2) in subjects with moderate to
severe psoriasis compared to matched healthy controls
